The vaccine, which has yet to advance beyond the Phase 1 trials, is being developed by the University of Queensland and Australian biotech company CSL. Australia hopes the vaccine will be available by mid-2021. In a statement, CSL 216 test participants reported no adverse effects and the vaccine was shown to have a “strong safety profile”. However, test data show that antibodies produced by the vaccine interfere with the diagnosis of HIV and lead to false positives in some HIV tests. C.S.L. Positive HIV tests in the community. “Follow-up tests have confirmed that there is no HIV virus. Some HIV tests are false positive. The vaccine is unlikely to cause infection,” the report added. Australian Prime Minister Scott Morrison told reporters Friday morning that the vaccine “will not be part of the nation’s vaccination program.” Australia pre-ordered 51 million doses of CSL vaccine in October. Morrison said Australia supported the four vaccines, but “at any point … believed all four vaccines would be available through that process.” “That’s why we spread our risk, that’s why we supported important projects, that’s why we were already prepared to make sure we could tackle any problem,” he said. In addition to the University of Queensland vaccine, Australia had previously ordered 73.8 million doses of Astrogeneca and NovaVox vaccines. Following the announcement by Australian Health Minister Greg Hunt, Australia received $ 11 million from Astrogeneka and Novox. A vaccine must pass three stages of testing, which is considered for approval for general use. Australia has not yet approved a candidate for the corona virus vaccine. The vaccine is the result of technology used to generate false positive HIV results, Adam Taylor, head of early industry research on emerging viruses at Griffith University’s Menzies Health Institute. “The (vaccine) molecule clamp is made from an HIV protein, which is automatically harmless. The molecule clamp stabilizes the corona virus spike protein and provides the body with a good immune system, which is why clamp technology is so important,” Taylor said. Some Australian health experts have praised Queensland University researchers for completing a test that showed that the clamp sample vaccine against the corona virus showed “good protection and immune response” against early clinical trials and was unlikely to produce a positive result for HIV. “While this may seem counter-intuitive, from a research ethic point of view, it is a success,” Diego Silva, a health ethics expert at the University of Sydney School of Public Health, said in an email statement. .
Source